Hello! Welcome to the official website of Betta Pharmaceuticals!
Service Hotline:+86-571-86130357     Add to Favorites | Online Feedback 中文

Betta Pharmaceuticals Co., Ltd. was established in 2003 and is headquartered in Hangzhou, Zhejiang. It is a national high-tech enterprise, established by the experienced talent team of returnees, with research and development (R&D) of innovative drugs as its core focus, integrating R&D, manufacturing and marketing functions. On Nov. 7th , 2016, Betta Pharmaceuticals was successfully listed on the Shenzhen Stock Exchange with the stock code: 300558.SZ.

The company has more than 1,400 employees, and has established a senior executive team for innovative drug discovery and commercialization, including dozens of returnees (Ph.D.). The company has set up R&D centers in Beijing, Hangzhou and San Diego, U.S.A.. The company independently developed China's first small molecule targeted anti-cancer drug——icotinib hydrochloride (trade name: Conmana), and was approved by the National Medical Products Administration (NMPA) in June 2011. Since its market launch, more than 250,000 lung cancer patients have been treated with the product and more than 5 million medicines have been offered through Betta’s patient assistance program. The market value has reached more than 10 billion RMB. Conmana has won the Gold Prize of China Patent Award twice as well as the China Industrial Award. It has also been awarded for the National Prize for Progress in Science and Technology, as the first such award granted to the China's chemical pharmaceutical industry and to a Zhejiang enterprise

The company continues to invest in innovative drug development for cancer, diabetes and other major diseases that seriously affect human health. In 2017, Betta invested 380 million RMB to its R&D, accounting for 37% of its revenue. Betta’s R&D expenditure increased to 590 million RMB in 2018 and to 48% of its revenue. Currently, there are more than 30 innovative drug projects in Betta’s pipeline with 11 in clinical stages, including 4 in phase III clinical trials. The new drug application (NDA) of ensatinib has been submitted and was granted a priority review by the NMPA. The global multi-center phase III clinical trial of ensartinib is ongoing and it is expected to be the first lung cancer-targeting innovative drug to be marketed globally by a Chinese pharmaecutical company.

Actively responding the call from the industry, the company also set up a healthcare innovation incubator——Betta Dreamworks, to help more scientists achieve their dreams of innovation and entrepreneurship.